G1 THERAPEUTICS INC (GTHX) Fundamental Analysis & Valuation

NASDAQ:GTHX • US3621LQ1099

Current stock price

7.15 USD
0 (0%)
At close:
7.14 USD
-0.01 (-0.14%)
After Hours:

This GTHX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. GTHX Profitability Analysis

1.1 Basic Checks

  • In the past year GTHX has reported negative net income.
  • GTHX had a negative operating cash flow in the past year.
  • GTHX had negative earnings in each of the past 5 years.
  • GTHX had a negative operating cash flow in each of the past 5 years.
GTHX Yearly Net Income VS EBIT VS OCF VS FCFGTHX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -45.36%, GTHX is in line with its industry, outperforming 52.20% of the companies in the same industry.
  • GTHX has a worse Return On Equity (-182.03%) than 67.14% of its industry peers.
Industry RankSector Rank
ROA -45.36%
ROE -182.03%
ROIC N/A
ROA(3y)-58.78%
ROA(5y)-52.55%
ROE(3y)-151.24%
ROE(5y)-111.52%
ROIC(3y)N/A
ROIC(5y)N/A
GTHX Yearly ROA, ROE, ROICGTHX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150 -200

1.3 Margins

  • GTHX has a better Gross Margin (89.44%) than 92.44% of its industry peers.
  • GTHX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 89.44%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GTHX Yearly Profit, Operating, Gross MarginsGTHX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. GTHX Health Analysis

2.1 Basic Checks

  • GTHX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, GTHX has more shares outstanding
  • GTHX has a worse debt/assets ratio than last year.
GTHX Yearly Shares OutstandingGTHX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
GTHX Yearly Total Debt VS Total AssetsGTHX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

  • GTHX has an Altman-Z score of -8.24. This is a bad value and indicates that GTHX is not financially healthy and even has some risk of bankruptcy.
  • GTHX has a Altman-Z score of -8.24. This is in the lower half of the industry: GTHX underperforms 72.76% of its industry peers.
  • A Debt/Equity ratio of 1.34 is on the high side and indicates that GTHX has dependencies on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 1.34, GTHX is doing worse than 80.14% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.34
Debt/FCF N/A
Altman-Z -8.24
ROIC/WACCN/A
WACC11.45%
GTHX Yearly LT Debt VS Equity VS FCFGTHX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 2.48 indicates that GTHX has no problem at all paying its short term obligations.
  • GTHX has a Current ratio of 2.48. This is in the lower half of the industry: GTHX underperforms 71.53% of its industry peers.
  • A Quick Ratio of 2.12 indicates that GTHX has no problem at all paying its short term obligations.
  • With a Quick ratio value of 2.12, GTHX is not doing good in the industry: 73.81% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.48
Quick Ratio 2.12
GTHX Yearly Current Assets VS Current LiabilitesGTHX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. GTHX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 49.71% over the past year.
  • The Revenue for GTHX has decreased by -34.74% in the past year. This is quite bad
  • GTHX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 22.13% yearly.
EPS 1Y (TTM)49.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-171.43%
Revenue 1Y (TTM)-34.74%
Revenue growth 3Y22.13%
Revenue growth 5YN/A
Sales Q2Q%-60.97%

3.2 Future

  • GTHX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.36% yearly.
  • GTHX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.53% yearly.
EPS Next Y55.71%
EPS Next 2Y43.4%
EPS Next 3Y30.77%
EPS Next 5Y20.36%
Revenue Next Year-8.96%
Revenue Next 2Y8.16%
Revenue Next 3Y10.3%
Revenue Next 5Y15.53%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
GTHX Yearly Revenue VS EstimatesGTHX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
GTHX Yearly EPS VS EstimatesGTHX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

2

4. GTHX Valuation Analysis

4.1 Price/Earnings Ratio

  • GTHX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • GTHX is valuated quite expensively with a Price/Forward Earnings ratio of 133.52.
  • Based on the Price/Forward Earnings ratio, GTHX is valued cheaply inside the industry as 90.86% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of GTHX to the average of the S&P500 Index (38.51), we can say GTHX is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 133.52
GTHX Price Earnings VS Forward Price EarningsGTHX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GTHX Per share dataGTHX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates GTHX does not grow enough to justify the current Price/Earnings ratio.
  • GTHX's earnings are expected to grow with 30.77% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.4%
EPS Next 3Y30.77%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GTHX Dividend Analysis

5.1 Amount

  • No dividends for GTHX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

GTHX Fundamentals: All Metrics, Ratios and Statistics

G1 THERAPEUTICS INC

NASDAQ:GTHX (9/17/2024, 8:10:49 PM)

After market: 7.14 -0.01 (-0.14%)

7.15

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08
Earnings (Next)10-30
Inst Owners1.72%
Inst Owner Change-96.06%
Ins Owners13.3%
Ins Owner Change0%
Market Cap377.23M
Revenue(TTM)58.20M
Net Income(TTM)-44.77M
Analysts74.55
Price Target7.29 (1.96%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.61%
Min EPS beat(2)4.63%
Max EPS beat(2)40.58%
EPS beat(4)3
Avg EPS beat(4)16.53%
Min EPS beat(4)-4.3%
Max EPS beat(4)40.58%
EPS beat(8)7
Avg EPS beat(8)33.92%
EPS beat(12)10
Avg EPS beat(12)23.38%
EPS beat(16)14
Avg EPS beat(16)22.11%
Revenue beat(2)0
Avg Revenue beat(2)-3.93%
Min Revenue beat(2)-6.99%
Max Revenue beat(2)-0.87%
Revenue beat(4)1
Avg Revenue beat(4)-2.9%
Min Revenue beat(4)-15.25%
Max Revenue beat(4)11.53%
Revenue beat(8)4
Avg Revenue beat(8)6.13%
Revenue beat(12)7
Avg Revenue beat(12)4.65%
Revenue beat(16)10
Avg Revenue beat(16)136.37%
PT rev (1m)58.89%
PT rev (3m)-15.88%
EPS NQ rev (1m)0%
EPS NQ rev (3m)24.07%
EPS NY rev (1m)-2.21%
EPS NY rev (3m)24.34%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.2%
Revenue NY rev (1m)2.96%
Revenue NY rev (3m)1.77%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 133.52
P/S 6.48
P/FCF N/A
P/OCF N/A
P/B 15.34
P/tB 15.34
EV/EBITDA N/A
EPS(TTM)-0.86
EYN/A
EPS(NY)0.05
Fwd EY0.75%
FCF(TTM)-0.71
FCFYN/A
OCF(TTM)-0.71
OCFYN/A
SpS1.1
BVpS0.47
TBVpS0.47
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -45.36%
ROE -182.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 89.44%
FCFM N/A
ROA(3y)-58.78%
ROA(5y)-52.55%
ROE(3y)-151.24%
ROE(5y)-111.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 1.34
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.48
Quick Ratio 2.12
Altman-Z -8.24
F-Score3
WACC11.45%
ROIC/WACCN/A
Cap/Depr(3y)32.08%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.33%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)49.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-171.43%
EPS Next Y55.71%
EPS Next 2Y43.4%
EPS Next 3Y30.77%
EPS Next 5Y20.36%
Revenue 1Y (TTM)-34.74%
Revenue growth 3Y22.13%
Revenue growth 5YN/A
Sales Q2Q%-60.97%
Revenue Next Year-8.96%
Revenue Next 2Y8.16%
Revenue Next 3Y10.3%
Revenue Next 5Y15.53%
EBIT growth 1Y43.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year44.15%
EBIT Next 3Y133.69%
EBIT Next 5Y24.98%
FCF growth 1Y74.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y74.2%
OCF growth 3YN/A
OCF growth 5YN/A

G1 THERAPEUTICS INC / GTHX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for G1 THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to GTHX.


What is the valuation status of G1 THERAPEUTICS INC (GTHX) stock?

ChartMill assigns a valuation rating of 2 / 10 to G1 THERAPEUTICS INC (GTHX). This can be considered as Overvalued.


Can you provide the profitability details for G1 THERAPEUTICS INC?

G1 THERAPEUTICS INC (GTHX) has a profitability rating of 1 / 10.


Can you provide the financial health for GTHX stock?

The financial health rating of G1 THERAPEUTICS INC (GTHX) is 2 / 10.